Elsevier

Seminars in Perinatology

Volume 21, Issue 1, February 1997, Pages 53-62
Seminars in Perinatology

Platelet disorders in newborn infants: Diagnosis and management

https://doi.org/10.1016/S0146-0005(97)80020-1Get rights and content

Platelets are small, disc-shaped, anucleated cells formed by fragmentation of megakaryocytes in the bone marrow. They circulate in blood with a lifespan of 7 to 10 days and, together with fibrin, form hemostatic plugs at sites of vessel injury. Abnormalities of platelets, either quantitative or qualitative, may cause clinically significant bleeding with resultant morbidity and, on occasion, mortality. This review will focus on platelet disorders in neonates, defined as infants of up to 4 months of age. Special emphasis will be given to the physiology of platelet function in healthy and sick newborn infants. The review will be divided into sections as follows: role of platelets in hemostasis, platelet function in newborn infants, quantitative platelet disorders, qualitative platelet disorders, and platelet transfusion therapy.

References (80)

  • KatzJ et al.

    Normal coagulation findings, thrombocytopenia and peripheral hemoconcentration in neonatal polycythemia

    J Pediatr

    (1982)
  • CohenIJ et al.

    Thrombocytopenia in neonatal cold injury

    J Pediatr

    (1984)
  • BallinA et al.

    Reduction of platelet counts induced by mechanical ventilation in newborn infants

    J Pediatr

    (1987)
  • SegallML et al.

    Thrombocytopenia and pulmonary hypertension in the perinatal aspiration syndromes

    J Pediatr

    (1980)
  • CastleV et al.

    Frequency and mechanism of neonatal thrombocytopenia

    J Pediatr

    (1986)
  • CastleV et al.

    IIIIn-Oxine platelet survivals in thrombocytopenic infants

    Blood

    (1987)
  • AndrewM et al.

    Clinical impact of neonatal thrombocytopenia

    J Pediatr

    (1987)
  • MehtaP et al.

    Thrombocytopenia in the high-risk infant

    J Pediatr

    (1980)
  • CorbyDG et al.

    The effects of antenatal drug administration on aggregation of platelets of newborn infants

    J Pediatr

    (1971)
  • CorazzaMS et al.

    Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus

    J Pediatr

    (1984)
  • AndrewM et al.

    A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants

    J Pediatr

    (1993)
  • BlanchetteVS et al.

    Platelet transfusion therapy in newborn infants

    Transfus Med Rev

    (1995)
  • McIntoshS et al.

    Neonatal isoimmune purpura: Response to platelet infusions

    J Pediatr

    (1973)
  • KarpatkinM

    Corticosteroid therapy in thrombocytopenic infants of women with autoimmune thrombocytopenia

    J Pediatr

    (1984)
  • PackhamMA

    Role of platelets in thrombosis and hemostasis

    Can J Physiol Pharmacol

    (1994)
  • SiessW

    Molecular mechanisms of platelet activation

    Physiol Rev

    (1989)
  • AndrewM

    The hemostatic system in the infant

  • AndrewM

    Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients

    Thromb Haemostas

    (1995)
  • SuarezCR et al.

    Neonatal and maternal hemostasis. Value of molecular markers in the assessment of hemostatic status

  • SuarezCR et al.

    Neonatal and maternal platelets: Activation at time of birth

    Am J Hematol

    (1988)
  • RajasekharD et al.

    Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood

    Thromb Haemostas

    (1994)
  • AndrewM et al.

    Evaluation of an automated bleeding time device in the newborn

    Am J Hematol

    (1990)
  • AndrewM et al.

    Development of the human coagulation system in the full-term infant

    Blood

    (1987)
  • WeinsteinMJ et al.

    Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura

    Br J Hematol

    (1989)
  • KatzJA et al.

    Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma

    Blood

    (1989)
  • MullMM et al.

    Altered platelet function in newborns

    Pediatr Res

    (1970)
  • IsraelsSJ et al.

    Deficient collagen-induced activation in the newborn platelet

    Pediatr Res

    (1990)
  • IsraelsSJ et al.

    Contractile activity of neonatal platelets

    Pediatr Res

    (1987)
  • AlebouyehM et al.

    The effect of 5-hydroxytryptamine and epinephrine on newborn platelets

    Eur J Pediatr

    (1978)
  • CorbyDG et al.

    Neonatal platelet function: A membrane-related phenomenon?

    Haemostasis

    (1981)

    • Cited by (59)

    • Disorders of Coagulation in the Neonate

      2018, Hematology: Basic Principles and Practice

    • Disorders of Coagulation in the Neonate

      2017, Hematology: Basic Principles and Practice

    • Platelet Function in the Newborn

      2013, Platelets

    • Platelet Function in the Newborn

      2012, Platelets, Third Edition

    • A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population

      2011, Blood Cells, Molecules, and Diseases
      Citation Excerpt :

      We therefore calculate that the presence of all six MPL-associated polymorphisms present on the c.79 + 2T > A-bearing allele is a rare event and occurs in at most 0.4% of individuals of the AJ descent who do not carry the c.79 + 2T > A mutation. Thrombocytopenia is a common clinical problem observed in neonates and can be due to placental insufficiency, a congenital infection or an autoimmune or alloimmune response [28–31]. CAMT, which is caused by the homozygous or compound heterozygous presence of mutations in the thrombopoietin receptor-encoding gene, MPL, is viewed as a rare cause of thrombocytopenia in a neonate.

    • Advances and Controversies in Neonatal ICU Platelet Transfusion Practice

      2008, Advances in Pediatrics
      Citation Excerpt :

      A sensitivity analysis (Fig. 4 and Table 4) suggests that the platelet transfusions themselves likely were responsible for some fraction of the increasing mortality rate. Establishing NICU transfusion guidelines has been advocated as a way of improving practice and reducing unnecessary transfusions [47–54]. In 2002, Intermountain Healthcare, a not-for-profit healthcare organization in the Western United States, established and implemented a written set of NICU transfusion guidelines.

    View all citing articles on Scopus
    View full text
    Copyright © 1997 Published by Elsevier Inc.